Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 9:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Transplant Failure Clear all
Recruiting Phase 1Phase 2 Interventional

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

NCT03128996
View directory record Official record
Conditions
Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders
Interventions
RIC regimen, GVHD prophylaxis regimen
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2033
U.S. locations
4
States / cities
New Haven, Connecticut • Wilmington, Delaware • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 9:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Renal Allograft Tolerance Through Mixed Chimerism

NCT01780454
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
MEDI-507, Rituximab, Total Body Irradiation, Thymic Irradiation
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Jun 10, 2026, 9:26 PM EDT
Completed No phase listed Observational

Clinical Trials in Organ Transplantation Extension Study

NCT04126746
View directory record Official record
Conditions
Lung Transplant Failure and Rejection
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Jun 10, 2026, 9:26 PM EDT
Recruiting Phase 2 Interventional

Haploidentical HCT for Severe Aplastic Anemia

NCT04558736
View directory record Official record
Conditions
Aplastic Anemia, Bone Marrow Failure Syndrome
Interventions
Anti-Thymocyte Globulin (Rabbit), Fludarabine, Cyclophosphamide, Mesna, G-CSF, Total Lymphoid Irradiation (TLI), CliniMACS, HPC, A Infusion, CD45RA-depleted DLI
Drug · Radiation · Device + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Jun 10, 2026, 9:26 PM EDT
Terminated Not applicable Interventional

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

NCT00290628
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Diamond-blackfan Anemia, Fanconi Anemia, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, filgrastim, melphalan, methylprednisolone, mycophenolate mofetil, radiation therapy, umbilical cord blood transplantation
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Jun 10, 2026, 9:26 PM EDT
Completed No phase listed Observational

Intraoperative Echocardiographic Evaluation of Pulmonary Vein Velocities and Outcomes in Lung Transplantation

NCT03052153
View directory record Official record
Conditions
Lung Transplant Failure
Interventions
No investigational intervention performed for this study
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Jun 10, 2026, 9:26 PM EDT
Completed Early Phase 1 Interventional

A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation

NCT04682509
View directory record Official record
Conditions
ESRD
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Jun 10, 2026, 9:26 PM EDT
Withdrawn Not applicable Interventional

Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant

NCT00167791
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
rituximab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jun 10, 2026, 9:26 PM EDT
Terminated Phase 2 Interventional Results available

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

NCT02322190
View directory record Official record
Conditions
Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
Interventions
Extracorporeal Photopheresis (ECP), Methoxsalen
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Jun 10, 2026, 9:26 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

RaDIANT Health Systems Intervention

NCT07033117
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Kidney Disease
Interventions
Performance Feedback Reports on Referral and Evaluation Closures, Dialysis Facility Awareness Campaign, Patient Contact via Preferred Method, Phone Call to Dialysis Facility During the Patient's Dialysis Session, Phone Call to Provider, Transplant Referral Communication Platforms or Email to Communicate Patient Status and No-Show, Audit and Tracking of Patient Contact Attempts Prior to Referral Closure
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
14,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 10, 2026, 9:26 PM EDT
Completed No phase listed Observational

Live Kidney Donor Study -Renal Function Study

NCT01158742
View directory record Official record
Conditions
Kidney Donation, Kidney Failure, Kidney Transplantation
Interventions
Glomerular Filtration Rate with Iothalamate, Glomerular Filtration Rate with Iohexol
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Jun 10, 2026, 9:26 PM EDT
Terminated Not applicable Interventional

Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

NCT01033357
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Hyperplasia
Interventions
Graft, Vascular Wrap, Lifespan® ePTFE Vascular Graft Only
Device
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
30
States / cities
Fresno, California • Inglewood, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jun 10, 2026, 9:26 PM EDT
Terminated Phase 4 Interventional Results available

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

NCT03208127
View directory record Official record
Conditions
End Stage Liver Disease, Hepatitis C
Interventions
Treatment with Direct Acting Antiviral tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Jun 10, 2026, 9:26 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease

NCT01840956
View directory record Official record
Conditions
End-stage Renal Disease, Kidney Failure, Chronic
Interventions
HAVG
Biological
Lead sponsor
Humacyte, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Durham, North Carolina • Houston, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Jun 10, 2026, 9:26 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

NCT03380962
View directory record Official record
Conditions
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Jun 10, 2026, 9:26 PM EDT
Completed Not applicable Interventional

Use of EL-FIT App to Promote Physical Activity

NCT04604860
View directory record Official record
Conditions
End Stage Liver DIsease, Cirrhosis, Liver
Interventions
Fitness intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Jun 10, 2026, 9:26 PM EDT
Completed Phase 1 Interventional

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

NCT02960646
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Aplastic Anemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Therapy-Related Myelodysplastic Syndrome
Interventions
Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Rituximab, Tacrolimus, Total-Body Irradiation
Drug · Biological · Other + 2 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jun 10, 2026, 9:26 PM EDT
Completed No phase listed Observational

Creation of a Digital Heart Failure Registry Using a Novel Mobile Health Platform: HUGO-HF

NCT03810638
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Jun 10, 2026, 9:26 PM EDT
Completed Not applicable Interventional

Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia

NCT00005891
View directory record Official record
Conditions
Fanconi's Anemia
Interventions
cyclophosphamide, Allogeneic Bone Marrow Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
0 Years to 54 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 9:26 PM EDT
Completed Phase 4 Interventional

A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

NCT00510913
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation
Interventions
tacrolimus
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
12 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2007 · Synced Jun 10, 2026, 9:26 PM EDT
Completed Not applicable Interventional

Enhancing Education Regarding Living Donor Transplant Among Kidney Transplant Candidates

NCT01261910
View directory record Official record
Conditions
Kidney Transplant, Living-Donor Kidney Transplant, Chronic Kidney Disease, End-stage Renal Disease
Interventions
Intensive initial education
Behavioral
Lead sponsor
St. Barnabas Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Livingston, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 27, 2014 · Synced Jun 10, 2026, 9:26 PM EDT
Completed No phase listed Observational

Correlation Between Release of Cytokines From Liver Graft and Hemodynamic Instability

NCT01120743
View directory record Official record
Conditions
Liver Transplantation
Interventions
Not listed
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Jun 10, 2026, 9:26 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Stem Cell Transplantation for Fanconi Anemia

NCT00167206
View directory record Official record
Conditions
Fanconi Anemia
Interventions
Hematopoietic Stem Cell Transplant, Thymic Shielding During Radiation, Total Body Irradiation, Cyclophosphamide, Fludarabine
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Day to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2019 · Synced Jun 10, 2026, 9:26 PM EDT
Recruiting Not applicable Interventional

CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure

NCT06569082
View directory record Official record
Conditions
Graft Failure, Poor Graft Function
Interventions
CD34+ Selected Donor Cell Boost, Blood Stem Cell Infusion
Device · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jun 10, 2026, 9:26 PM EDT